The DOI matches its Crossref record.
Human brain fluoxetine concentrations
Abstract
Data on 22 subjects treated with fluoxetine suggest that magnetic resonance spectroscopy (MRS) of fluorine-19 can measure brain concentrations of fluoxetine/norfluoxetine in vivo. Fluoxetine accumulates in the human brain relative to plasma, with brain concentrations of fluoxetine/norfluoxetine ranging up to 10.7 micrograms/ml. Brain concentrations may reach a plateau between 6 and 8 months of treatment. The apparent concentration in brain relative to plasma is 20:1, roughly parallel to brain antidepressant concentration ratios in animal studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Fluorine (19F) MRS and MRI in biomedicine
Ruiz‐Cabello, J., Barnett, B. P., Bottomley, P. A., & Bulte, J. W. M. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1570 · Cited by 489
Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype
Heurteaux, C., Lucas, G., Guy, N., El Yacoubi, M., Thümmler, S., Peng, X.-D., Noble, F., Blondeau, N., Widmann, C., Borsotto, M., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1749 · Cited by 374
Inhibition of Neuronal Na+ Channels by Antidepressant Drugs
Pancrazio, J. J., Kamatchi, G. L., Roscoe, A. K., & Lynch, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37206-4 · Cited by 311
Normann, C., Frase, S., Haug, V., von Wolff, G., Clark, K., Münzer, P., Dorner, A., Scholliers, J., Horn, M., Vo Van, T., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.008 · Cited by 56
Impact of Lipid Raft Integrity on 5-HT3 Receptor Function and its Modulation by Antidepressants
Nothdurfter, C., Tanasic, S., Di Benedetto, B., Rammes, G., Wagner, E.-M., Kirmeier, T., Ganal, V., Kessler, J. S., Rein, T., Holsboer, F., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.20 · Cited by 43
Rethinking the role of TRKB in the action of antidepressants and psychedelics
Brunello, C. A., Cannarozzo, C., & Castrén, E. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.011 · Cited by 31
Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines
Mundalil Vasu, M., Anitha, A., Takahashi, T., Thanseem, I., Iwata, K., Asakawa, T., & Suzuki, K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164425 · Cited by 17
Cannarozzo, C., Rubiolo, A., Casarotto, P., & Castrén, E. (2022) · doi:10.1101/2022.04.06.487292 · Cited by 2
“Ketamine readily penetrates the brain to achieve concentrations needed to bind to TRKB and NMDARs, but for fluoxetine, concentrations needed to reach TRKB binding build up gradually over several days and weeks of treatment (Karson et al., 1993), which may at least partially explain the need of long-term treatment with…”
Background
Metadata
- Venue
- The Journal of Neuropsychiatry and Clinical Neurosciences
- Published
- 1993-08-01
- Volume
- 5
- Issue
- 3
- Pages
- 322-329
- ISSN
- 0895-0172 (ISSN-L)
- 1545-7222
- OpenAlex
- W2465651915
- Cited by
- 200
- References
- 0
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.